Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature

J Pediatr Surg. 2012 Jun;47(6):e31-40. doi: 10.1016/j.jpedsurg.2012.02.023.

Abstract

Perivascular epithelioid cell tumors (PEComas) include different morphological entities originating from perivascular epithelioid cells. Their clinical behavior is not predictable, and there are no strict histologic criteria for malignancy, although larger tumors with infiltrative growth, hypercellularity, cellular atypia, atypical mitoses, and necrosis generally have a malignant course. Pediatric PEComas are rare, with less than 40 cases reported, mostly in children older than 5 years. We describe a case of malignant PEComa of the ligamentum teres in a 2-year-old girl, characterized by the occurrence of local relapse after primary treatment with chemotherapy and surgery and poor response to imatinib mesilate and temsirolimus used after further analyses confirmed p70S6K expression involved in the mTOR pathway. The girl was eventually treated with a debulking surgical procedure and is now alive with disease 6 years after diagnosis. Literature data of children affected by PEComas were also analyzed, trying to identify pathologic characteristics that could predict their course and therapeutic options. Histologically, they may be differentiated in 3 prognostic categories: (1) benign, lacking unfavorable morphological markers; (2) with uncertain malignant potential, carrying 1 unfavorable marker; and (3) malignant, with at least 2 unfavorable markers. In the literature, 9% of cases occurred as a second malignancy probably because of genomic instability related to treatment. Their different biology and the potential value of targeted therapies remain to be explored. The indolent evolution in our patient was similar to that reported in some other cases in the literature. In terms of treatment, the present case suggests a minor response to temsirolimus compared with the adult population.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Abdominal Neoplasms / diagnosis
  • Abdominal Neoplasms / diagnostic imaging
  • Abdominal Neoplasms / drug therapy
  • Abdominal Neoplasms / pathology
  • Abdominal Neoplasms / surgery*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzamides
  • Biopsy
  • Child, Preschool
  • Combined Modality Therapy
  • Diagnostic Errors
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Imatinib Mesylate
  • Intestinal Obstruction / etiology
  • Ligaments / pathology*
  • Ligaments / surgery
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Neoplasm Recurrence, Local
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery
  • Perivascular Epithelioid Cell Neoplasms / diagnosis
  • Perivascular Epithelioid Cell Neoplasms / diagnostic imaging
  • Perivascular Epithelioid Cell Neoplasms / drug therapy
  • Perivascular Epithelioid Cell Neoplasms / pathology
  • Perivascular Epithelioid Cell Neoplasms / secondary
  • Perivascular Epithelioid Cell Neoplasms / surgery*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / therapeutic use
  • Radiography
  • Sarcoma, Clear Cell / diagnosis
  • Sirolimus / administration & dosage
  • X Chromosome Inactivation

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Etoposide
  • Imatinib Mesylate
  • Sirolimus